Structure Therapeutics' (GPCR) subsidiary Gasherbrum Bio signed a patent license agreement with Genentech, granting Genentech ...

Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) has issued an update. On December 30, 2025, Gasherbrum Bio, a subsidiary of Structure ...

Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...

Structure Therapeutics, through its subsidiary Gasherbrum, entered into a non-exclusive patent license with Genentech, the US ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 7.69% ...

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) ...

Scientists reveal how G protein-coupled receptors, major therapeutic drug targets, decode critical properties of their ligands. Through an international collaboration, scientists at St. Jude ...

Structure Therapeutics has a promising pipeline of product candidates, including GSBR-1290, a GLP-1R agonist for diabetes and obesity, and APJR and LPA1R agonists and antagonists for various ...